July 10, 2014 2:58 AM ET

Biotechnology

Company Overview of VaxInnate, Inc.

Company Overview

VaxInnate, Inc., a biotechnology company, engages in the development and production of vaccines for pandemic and seasonal influenza diseases. Its products include Flagellin.HuHA and flagellin.AvHA, which are fusion proteins linking a potent immune stimulator, the bacterial protein flagellin, with immunoprotective domain of viral hemagglutinin. The company's products are used in the treatment of various diseases, including bacterial, viral, and parasitic infections. VaxInnate, Inc. was founded in 2002 and is headquartered in Cranbury, New Jersey.

3 Cedar Brook Drive

Suite 1

Cranbury, NJ 08512

United States

Founded in 2002

Phone:

609-860-2260

Fax:

609-860-2290

Key Executives for VaxInnate, Inc.

Chief Executive Officer
Age: 59
Scientific Founder
Scientific Founder
Chief Financial Officer
Age: 53
Vice President of Business Development
Age: 55
Compensation as of Fiscal Year 2014.

VaxInnate, Inc. Key Developments

VaxInnate Begins Phase I Clinical Trial to Evaluate Quadrivalent Vaccine for Prevention of Seasonal Flu

VaxInnate Corporation announced that enrollment has commenced in a Phase 1 clinical trial to evaluate VAX2012Q, a recombinant quadrivalent vaccine in development for the prevention of seasonal influenza. The VAX2012Q clinical trial is being funded in whole with federal funds from the Office of the Assistant Secretary for Preparedness and Response, Biomedical Advanced Research and Development Authority (BARDA), Department of Health and Human Services (HHS), under Contract No. HHSO100201100011C. The trial, which is taking place at four sites in the United States, will evaluate the safety and immunogenicity of VAX2012Q. VAX2012Q is a dose escalation study. Up to 320 healthy adults aged 18-40 will receive VAX2012Q by intramuscular injection. The subjects will be evaluated in the clinic 21 days and six months post-vaccination, and followed for one year. The study is expected to yield data that will enable VaxInnate to select the appropriate dose of VAX2012Q for further development. Results are anticipated by the end of 2014. VaxInnate's technology platform is based on proprietary Toll-like Receptor (TLR) technology, which potentiates the immune response. The TLR technology genetically fuses vaccine antigens to the bacterial protein flagellin, and this sequentially triggers the innate and adaptive immune systems. Using this technology, vaccines can be produced using low-cost, highly-scalable, recombinant DNA techniques, thus avoiding many of the challenges of conventional vaccine production. This technology has the potential for production of significantly greater quantities of vaccine in extremely rapid timeframes, with very low infrastructure costs.

VaxInnate Corporation Presents at World Vaccine Congress Washington 2013, Apr-16-2013 through Apr-18-2013

VaxInnate Corporation Presents at World Vaccine Congress Washington 2013, Apr-16-2013 through Apr-18-2013. Venue: Gaylord National Hotel and Convention Center, Washington, District Of Columbia, United States. Presentation Date & Speakers: Apr-17-2013, Wayne Pisano, President & CEO.

VaxInnate, Inc. Presents at World Vaccine Congress Washington 2013, Apr-17-2013 04:40 PM

VaxInnate, Inc. Presents at World Vaccine Congress Washington 2013, Apr-17-2013 04:40 PM. Venue: Gaylord National Hotel and Convention Center, Washington, District Of Columbia, United States. Speakers: Wayne F. Pisano, Chief Executive Officer, President and Director.

Similar Private Companies By Industry

Company Name Region
CSL Plasma, Inc. United States
Alpha-Beta Technology United States
NexGenix Pharmaceuticals Holdings, Inc. United States
ImmuneWorks, Inc. United States
Rosetta Inpharmatics LLC United States

Recent Private Companies Transactions

Type
Date
Target
No transactions available in the past 12 months.
 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup

Most Searched Private Companies

Company Name Geographic Region
NYC2012, Inc. United States
Lawyers Committee for Civil Rights Under Law United States
Bertelsmann AG Europe
Rush University United States
Citizens Budget Commission United States

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact VaxInnate, Inc., please visit www.vaxinnate.com. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.